NO20072882L - Defekte influensaviruspartikler. - Google Patents
Defekte influensaviruspartikler.Info
- Publication number
- NO20072882L NO20072882L NO20072882A NO20072882A NO20072882L NO 20072882 L NO20072882 L NO 20072882L NO 20072882 A NO20072882 A NO 20072882A NO 20072882 A NO20072882 A NO 20072882A NO 20072882 L NO20072882 L NO 20072882L
- Authority
- NO
- Norway
- Prior art keywords
- influenza virus
- influenza
- defective
- nucleic acid
- provides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16141—Use of virus, viral particle or viral elements as a vector
- C12N2760/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04105696 | 2004-11-11 | ||
US62687804P | 2004-11-12 | 2004-11-12 | |
EP05105708 | 2005-06-27 | ||
US69443105P | 2005-06-28 | 2005-06-28 | |
PCT/EP2005/055808 WO2006051069A2 (fr) | 2004-11-11 | 2005-11-08 | Particules du virus de la grippe défectif |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20072882L true NO20072882L (no) | 2007-08-03 |
Family
ID=36228630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20072882A NO20072882L (no) | 2004-11-11 | 2007-06-06 | Defekte influensaviruspartikler. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20080292658A1 (fr) |
EP (2) | EP1812564A2 (fr) |
JP (2) | JP4986859B2 (fr) |
KR (1) | KR20070100882A (fr) |
AU (1) | AU2005303817B8 (fr) |
CA (1) | CA2587451A1 (fr) |
IL (2) | IL182817A (fr) |
MX (1) | MX2007005719A (fr) |
NO (1) | NO20072882L (fr) |
NZ (1) | NZ555118A (fr) |
WO (1) | WO2006051069A2 (fr) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL213926B1 (pl) | 2001-01-19 | 2013-05-31 | Vironovative Bv | Wyizolowany ssaczy metapneumowirus o ujemnej pojedynczej nici RNA (MPV), kompozycja immunogenna, wyizolowane kwasy nukleinowe, sposoby wykrywania ssaczego metapneumowirusa, wektor, komórka gospodarza, wyizolowane bialko, przeciwcialo, sposób wirologicznego diagnozowania infekcji MPV, sposób serologicznego diagnozowania infekcji MPV, kompozycja farmaceutyczna, zestaw diagnostyczny oraz zastosowanie kompozycji farmaceutycznej |
EP1364006A2 (fr) | 2001-02-23 | 2003-11-26 | Wisconsin Alumni Research Foundation | Methode d'identification de cellulles mutantes avec acid sialic modifie |
EP3009507B1 (fr) | 2002-02-13 | 2020-06-24 | Wisconsin Alumini Research Foundation | Signal d'incorporation de vecteurs de virus de la grippe |
CN101098958A (zh) | 2002-02-21 | 2008-01-02 | 免疫医疗疫苗公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途 |
US7682619B2 (en) | 2006-04-06 | 2010-03-23 | Cornell Research Foundation, Inc. | Canine influenza virus |
US8435508B2 (en) | 2006-05-24 | 2013-05-07 | The University Of Warwick | Cloned defective interfering influenza A virus |
GB2437799B (en) * | 2006-05-24 | 2008-08-13 | Univ Warwick | Defective interfering virus |
AU2007332987B2 (en) * | 2006-08-14 | 2013-01-10 | Massachusetts Institute Of Technology | Hemagglutinin polypeptides, and reagents and methods relating thereto |
US8597661B2 (en) | 2007-05-04 | 2013-12-03 | Wisconsin Alumni Research Foundation | Neuraminidase-deficient live influenza vaccines |
GB0822672D0 (en) | 2008-12-12 | 2009-01-21 | Univ Warwick | Anti-viral protection with viruses containing a defective genome |
EP2747778B1 (fr) * | 2011-08-26 | 2017-12-06 | Wisconsin Alumni Research Foundation | Virus de la grippe ayant un segment génique pb2 mutant en tant que vaccins vivants atténués |
SG11201406769RA (en) | 2012-05-10 | 2014-11-27 | Massachusetts Inst Technology | Agents for influenza neutralization |
US9878032B2 (en) * | 2013-07-19 | 2018-01-30 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
GB2522615A (en) * | 2014-01-16 | 2015-08-05 | Univ Warwick | Assay and medicament |
US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
US10323231B2 (en) | 2015-04-24 | 2019-06-18 | University Of Rochester | Attenuated influenza vaccines and uses thereof |
WO2017040203A1 (fr) | 2015-08-28 | 2017-03-09 | Yoshihiro Kawaoka | Génération de virus de la grippe infectieux à partir de pseudo-particules virales (vlp) |
CL2018003871A1 (es) * | 2018-12-28 | 2021-01-15 | Univ Pontificia Catolica Chile | Anticuerpos monoclonales específicos para el antígeno pb2 del virus de la influenza humana (flu), secuencias nucleotídicas; método y kit de diagnóstico de infección producida por flu |
EP3921413A1 (fr) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Lignée cellulaire humanisée |
US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
WO2023138651A1 (fr) * | 2022-01-19 | 2023-07-27 | Versitech Limited | Virus infectieux à cycle unique de conception rationnelle et procédés d'utilisation de ce virus |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5166057A (en) * | 1989-08-28 | 1992-11-24 | The Mount Sinai School Of Medicine Of The City University Of New York | Recombinant negative strand rna virus expression-systems |
CA2380514A1 (fr) * | 1999-07-30 | 2001-02-08 | George Gow Brownlee | Virus attenue de la grippe utilisable comme vaccin |
JP2005523698A (ja) * | 2002-04-26 | 2005-08-11 | メディミューン・ヴァクシンズ・インコーポレーテッド | インフルエンザウイルスの生産用多重プラスミドシステム |
ES2552687T3 (es) * | 2002-12-13 | 2015-12-01 | Alphavax, Inc. | Partículas alfavíricas y métodos de preparación |
CN1809633B (zh) * | 2003-04-23 | 2011-01-19 | 威斯康星旧生研究基金会 | 跨膜蛋白基因中含有突变的重组流感病毒 |
-
2005
- 2005-11-08 JP JP2007540638A patent/JP4986859B2/ja not_active Expired - Fee Related
- 2005-11-08 KR KR1020077013149A patent/KR20070100882A/ko active IP Right Grant
- 2005-11-08 CA CA002587451A patent/CA2587451A1/fr not_active Abandoned
- 2005-11-08 MX MX2007005719A patent/MX2007005719A/es active IP Right Grant
- 2005-11-08 NZ NZ555118A patent/NZ555118A/en not_active IP Right Cessation
- 2005-11-08 WO PCT/EP2005/055808 patent/WO2006051069A2/fr active Application Filing
- 2005-11-08 US US11/667,594 patent/US20080292658A1/en not_active Abandoned
- 2005-11-08 AU AU2005303817A patent/AU2005303817B8/en not_active Ceased
- 2005-11-08 EP EP05801665A patent/EP1812564A2/fr not_active Ceased
- 2005-11-08 EP EP10182312A patent/EP2272950A3/fr not_active Withdrawn
-
2007
- 2007-04-26 IL IL182817A patent/IL182817A/en not_active IP Right Cessation
- 2007-06-06 NO NO20072882A patent/NO20072882L/no not_active Application Discontinuation
-
2012
- 2012-01-27 JP JP2012015022A patent/JP2012110339A/ja not_active Withdrawn
- 2012-02-20 IL IL218203A patent/IL218203A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
JP4986859B2 (ja) | 2012-07-25 |
EP2272950A3 (fr) | 2011-07-20 |
JP2008519591A (ja) | 2008-06-12 |
AU2005303817B2 (en) | 2010-06-10 |
AU2005303817A1 (en) | 2006-05-18 |
IL182817A (en) | 2012-04-30 |
IL182817A0 (en) | 2007-08-19 |
AU2005303817B8 (en) | 2010-09-30 |
JP2012110339A (ja) | 2012-06-14 |
EP2272950A2 (fr) | 2011-01-12 |
US20080292658A1 (en) | 2008-11-27 |
WO2006051069A3 (fr) | 2006-07-20 |
EP1812564A2 (fr) | 2007-08-01 |
MX2007005719A (es) | 2007-10-04 |
IL218203A0 (en) | 2012-04-30 |
NZ555118A (en) | 2009-09-25 |
KR20070100882A (ko) | 2007-10-12 |
CA2587451A1 (fr) | 2006-05-18 |
WO2006051069A2 (fr) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20072882L (no) | Defekte influensaviruspartikler. | |
EP2078083A4 (fr) | Nouveau virus de la grippe canine et vaccin correspondant | |
UA94717C2 (ru) | Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины | |
AU2009303758A8 (en) | Benzoquinoline inhibitors of vesicular monoamine transporter 2 | |
WO2007118206A3 (fr) | Virus de la grippe canine | |
WO2007126810A3 (fr) | Virus de la grippe recombinants à haut titre pour vaccins | |
TW200732476A (en) | Functional influenza virus like particles (VLPs) | |
ES2510940A2 (es) | Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas | |
NO20082149L (no) | Hundeinfluensavirus og relaterte sammensetninger og fremgangsmater for bruk | |
EA201100795A1 (ru) | Фармацевтическая композиция эффективного ингибитора всг для перорального введения | |
WO2009050390A3 (fr) | Procede de production du virus de la grippe | |
NO20090723L (no) | Kondenserte heterosykliske derivater og fremgangsmater for anvendelse | |
WO2009026465A3 (fr) | Composition et procédés de fabrication et d'utilisation de protéines de la grippe | |
IL186611A0 (en) | Vaccine against pandemic strains of influenza viruses | |
EA202090984A1 (ru) | Диспергируемая в полости рта единица дозирования, содержащая эстетрольный компонент | |
WO2011158044A3 (fr) | Formulations respiratoires et composés destinés à être utilisés dans ces formulations | |
DE602006013117D1 (de) | Nipah-virus-impfstoffe | |
NO20075961L (no) | Materialer og fremgangsmater til kontroll av respiratorisk sykdom hos hundedyr | |
SG133531A1 (en) | Orodispersible pharmaceutical composition for oromucosal or sublingual administration of agomelatine | |
EA200970013A1 (ru) | Вакцинация против гриппа по схеме многократного введения с использованием безадъювантной дозы | |
JP2009511080A5 (fr) | ||
AU2011280259A8 (en) | Influenza vaccine | |
EA201290897A1 (ru) | Вакцины для пандемического гриппа | |
GT201400027A (es) | Acuosa suspensión concentrada que comprende un ácido sal de dodecilguanidina | |
NO20044547L (no) | Nye farmasoytiske sammensetninger inneholdende flibanserin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: ABBOT BIOLOGICALS BV, NL Owner name: ERASMUS UNIVERSITY MEDICAL CENTER, NL |
|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |